The Impact of Different Doses of Febuxostat on the Micro-Inflammatory State in Patients with Stage 3-5 Chronic Kidney Disease and Hyperuricemia Undergoing Maintenance Hemodialysis
The Impact of Different Doses of Febuxostat on the Micro-Inflammatory State in Patients with Stage 3-5 Chronic Kidney Disease and Hyperuricemia Undergoing Maintenance Hemodialysis
[Objective]To investigate the effects of different doses of febuxostat on the micro-inflammatory state in patients with stage 3-5 chronic kidney disease(CKD)accompanied by hyperuricemia undergoing maintenance hemodialy-sis(MHD).[Methods]A total of 114 patients undergoing MHD with stage 3-5 CKD and hyperuricemia were randomly divided into three groups:Group A(38 patients),treated with 40 mg/day of oral febuxostat;Group B(38 patients),treated with 80 mg/d of oral febuxostat;and Group C(38 patients),treated with 300 mg/d of oral allopurinol.After 24 weeks of treatment,the clinical efficacy,serum markers,and adverse drug reactions during the treatment period were compared among the three groups.[Results]There were no statistically significant differences in clinical efficacy among the three groups(P＞0.05).After treatment,the levels of serum uric acid,endothelin-1(ET-1),interleukin-10(IL-10),and neutrophil elastase(NE)decreased in all groups(P＜0.05),but there were no statistically significant differences between the groups(P＞0.05).The incidence of adverse reactions was also not significantly different among the groups(P＞0.05).[Conclusion]Different doses of febuxostat in patients undergoing MHD with stage 3-5 CKD and hyperuricemia can improve the micro-inflammatory state and reduce serum uric acid levels,with good efficacy and safety.Clinical treatment should be tailored to the specific circumstances of the patient.
维普
万方数据